Form 4: Veracyte SVP, General Counsel Annie McGuire Reports Stock Transactions

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports acquisition of shares through vesting of performance-based restricted stock units and subsequent withholding of shares for tax obligations.

Summary

• On February 27, 2025, Annie McGuire, SVP, General Counsel of Veracyte, Inc., acquired 13,466 shares of common stock upon vesting of performance-based restricted stock units (PSUs).
• On the same day, 7,000 shares were withheld to satisfy tax obligations related to the PSU vesting at a price of $33.84.
• Additionally, 8,255 shares were withheld on March 2, 2025, to cover tax obligations related to vesting of Restricted Stock Units (RSUs) at a price of $34.76.
• McGuire also purchased 370 shares of common stock on January 31, 2025, through the Employee Stock Purchase Plan.
• Following these transactions, McGuire directly owns 71,450 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions, with no inherent positive or negative sentiment. It reflects routine compensation and tax management activities.

Positives

• The acquisition of shares through PSU vesting indicates achievement of performance goals set by the Board of Directors.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's a standard practice for executives to receive stock-based compensation and manage their tax obligations through share withholding.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, particularly in the biotechnology and pharmaceutical industries, to align the interests of executives with those of shareholders.
• Companies like Exact Sciences, Genomic Health (acquired by Exact Sciences), and Myriad Genetics also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these grants vary depending on the company's specific goals and objectives.

Stakeholder Impact

• The transactions have a minor impact on shareholders, reflecting insider activity related to compensation and tax obligations.

Key Dates